biostudies-literatureMirelis JGInstituto de Salud Carlos III1183-1196https://www.ebi.ac.uk/biostudies/studies/S-EPMC9546008biostudies-literatureUnknown24(7)<h4>Aims</h4>Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non-ischaemic dilated cardiomyopathy (DCM). We investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM.<h4>Methods and results</h4>Outcomes of 600 patients with DCM (53.3 ± 14.1 years, 66% male) who underwent clinical CMR and genetic testing were retrospectively analysed. The primary endpoints were end-stage heart failure (ESHF) and malignant ventricular arrhythmias (MVA). During a median follow-up of 2.7 years (interquartile range 1.3-4.9), 24 (4.00%) and 48 (8.00%) patients had ESHF and MVA, respectively. In total, 242 (40.3%) patients had pathogenEuropean journal of heart failureCombination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.PMC9546008PI18/0004PI20/0320PI19/01283Garcia-Pavia PFernandez-Avila ACasas GCliment VGonzalez-Carrillo JPalomino-Doza JBarriales-Villa RMogollon-Jimenez MVNavarro MGarcia-Granja PEEspinosa MAEscobar-Lopez LRipoll-Vera TBrugada RPena-Pena MLOchoa JPGarcia-Alvarez AGallego-Delgado MCabrera-Borrego ERodriguez-Gonzalez ERodriguez-Palomares JFAlvarez-Barredo MDominguez FBayes-Genis AGarcia-Pinilla JMVillacorta EMora-Ayestaran NMirelis JGfalseCombination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.<h4>Aims</h4>Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non-ischaemic dilated cardiomyopathy (DCM). We investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM.<h4>Methods and results</h4>Outcomes of 600 patients with DCM (53.3 ± 14.1 years, 66% male) who underwent clinical CMR and genetic testing were retrospectively analysed. The primary endpoints were end-stage heart failure (ESHF) and malignant ventricular arrhythmias (MVA). During a median follow-up of 2.7 years (interquartile range 1.3-4.9), 24 (4.00%) and 48 (8.00%) patients had ESHF and MVA, respectively. In total, 242 (40.3%) patients had pathogen2022-01-01T00:00:00Z2022 Jul2025-04-19T04:47:50.325Z2025-04-19T04:47:50.325ZS-EPMC95460083548524110.1002/ejhf.2514